Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into an agreement with Scintec Diagnostics GmbH (‘Scintec’) to acquire TheraPharm GmbH (‘TheraPharm’), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.
The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology. TheraPharm is developing antibody MTR technology against CD66, a cell surface target highly expressed by neutrophils (a type of white blood cell) and tumor-infiltrating lymphocytes. As such, the technology has potentially very broad applications in the diagnosis and treatment of hematologic diseases (e.g. blood cancers), lymphoproliferative disorders and immune-mediated diseases (e.g. lupus, and multiple sclerosis). Of particular interest is the demonstrated use of the technology to safely and effectively perform bone marrow conditioning (BMC) prior to bone marrow stem cell transplant.
Telix CEO, Dr. Christian Behrenbruch stated, “Telix is committed to extending and improving the lives of patients with serious diseases. As such, the acquisition of TheraPharm and its MTR assets are uniquely aligned to Telix’s mission and technical strengths in antibody engineering and radiochemistry. TheraPharm’s technology has a significant role to play in BMC and stem cell transplantation across a broad range of blood cancers and rare diseases. The current approach to BMC employs highly toxic drugs that have a poor morbidity and mortality profile, and for which many patients are ineligible. MTR offers an excellent safety profile that may greatly expand the number of patients able to undergo life prolonging stem cell transplantation while greatly reducing the hospitalisation burden and cost associated with such procedures.”
TheraPharm co-founder and Managing Director, Dr. Klaus Bosslet added, “Over the past 5 years, TheraPharm, in collaboration with Dr. Kim Orchard from the University of Southampton (UK), has made excellent progress developing 90Y-besilesomab for the treatment of hematologic cancers and several related conditions including multiple myeloma, leukemia and amyloidosis. This unique asset is a logical addition to Telix’s portfolio, offering a potentially rapid development path to a first commercial indication for the treatment of patients with SALA, while at the same time having potentially broad applications for stem cell transplantation in patients with more common cancers of the blood, including multiple myeloma and leukemia. We look forward to joining the Telix team in order to expedite the development of products for this under-served field.”
Full transaction details, including financial terms, can be found via the Telix website and ASX portal here.
About Hematopoietic Stem Cell Transplant (HSCT)
Bone marrow conditioning (BMC) followed by hematopoietic stem cell transplantation (HSCT) is presently performed to treat patients with hematologic malignancies (blood cancers), with the objective of extending patient survival or achieving cure. HSCT is also performed for a broad range of non-cancer conditions. HSCT is preferentially performed in countries of high income (Europe >30,000, Americas >20,000, worldwide >65,000 p.a., respectively)
Wider cross-segment of population is addressing mental health through virtual care
Notable shifts in diagnoses include men with higher rates of family and relationship issues; women with increases in substance abuse
PURCHASE, NY, Oct. 21, 2020 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC) has released findings from its latest mental health data highlighting how the persistent issues of 2020 – including the economic, health, environmental and societal crises – are impacting the mental health of Americans, and showing how virtual care is stepping up to meet the growing need.
While there are consistencies with previously published studies demonstrating surging demand for mental health services among Gen Z and Millennials, use of Teladoc Health’s mental health services are now also being used at record rates by groups who have not been known for embracing mental health care in the past.
Virtual mental health care use broadens across ages, genders and socioeconomic backgrounds
Women have long been a mainstay of mental health visits, but total mental health virtual care visits for men have been outpacing women both in year-over-year growth and 2020 monthly growth, up 79% since January vs 75%1, for women. In addition, while Gen Z has seen the largest year-over-year growth rate, now accounting for 14% of total mental health visits, all age groups have been seeking mental health care at an increased rate. Especially notable are patients over 65, who have seen their visits increase 16% since June.
Additionally, a previously underserved demographic for mental health – the Medicaid population – is seeing significant growth, with the number of Medicaid members with access to Teladoc mental health telemedicine services more than doubling year-over-year. Many of these individuals are among those with significant and chronic medical issues, unmet health needs and the most likely to have been hit hard by the recent pandemic.
“The stress of the pandemic and the social issues we’ve been experiencing have led to a dramatic increase in people reaching out and seeking timely mental health support,” said Dr. Gustavo Kinrys, VP Teladoc Mental Health. “In parallel with this surging need, we’re witnessing growing comfort with virtual care, especially among older adults, giving many individuals who may not have sought mental health care in the past an extraordinary opportunity to put themselves on the right path to better health.”
Diagnoses shift as health, economic and social issues persist
While the current social environment has had a profound impact on the need for mental health, it has also driven shifts in the types of diagnoses being made. As people spend more time at home and without their typical support groups, diagnoses are changing in some expected and some unexpected ways.
Men are seeking care at a higher rate for family and relationship issues than women, with year-over-year visits up 5.5X among men versus 4.2X among women. 2
Growing rates of alcohol and substance abuse are being noted in women, who now make up 38% of those diagnosed